B7-H3: a robust target for immunotherapy in prostate cancer
- PMID: 38839545
- DOI: 10.1016/j.trecan.2024.05.003
B7-H3: a robust target for immunotherapy in prostate cancer
Abstract
B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.
Keywords: B7-H3; immunotherapy; prostate cancer.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors have no interests to declare.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
